Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics, Inc. (FLGT) is the issuer for a Rule 144 notice filed for the account of Hanlin Gao, an officer. The notice covers a proposed sale of 939 shares of common stock through Morgan Stanley Smith Barney LLC. These shares relate to equity compensation, including restricted stock/RSUs that vested on February 26, 2024, from which 21,146 shares were acquired.
The filer also reports prior sales in the last three months of 945 shares and 1,688 shares of FLGT common stock. According to the statement, the current proposed sale and recent sales were executed as "sell to cover" transactions to satisfy tax withholding obligations tied to RSU vesting, and are described as not representing discretionary trades by the reporting person.
Fulgent Genetics, Inc. (FLGT) received a notice under Rule 144 that Jian Xie plans to sell 1,193 shares of common stock through Morgan Stanley Smith Barney LLC. The shares derive from 25,350 shares of restricted stock that vested on February 26, 2024 as equity compensation.
The filing states that this planned sale and prior sales over the past three months were made under "sell to cover" transactions to satisfy tax withholding obligations related to Restricted Stock Units, and are not discretionary trades by the reporting person. Fulgent Genetics had 27,515,293 shares of common stock outstanding as of August 27, 2026.
Fulgent Genetics reported second quarter 2026 results with revenue of $85.4 million, up from $81.8 million a year earlier, and a GAAP net loss of $29.5 million, or $(1.05) per share. GAAP gross margin was 30.1%, non-GAAP gross margin 31.3%, and non-GAAP net loss $16.2 million.
The company repurchased approximately 1.5 million shares for $23.8 million in the quarter and ended with $551.5 million in cash, cash equivalents, restricted cash and marketable securities, excluding an anticipated $106.1 million tax refund. For 2026, management guides revenue to $330–$340 million, non-GAAP loss of $63–$67 million, non-GAAP loss per share of $2.22–$2.35 and year-end cash of about $610 million. Management linked the guidance revision to processing delays during the final phase of its billing and revenue cycle transition that affected collection rates.
In its therapeutics segment, Fulgent highlighted Phase 2 data for FID‑007 in recurrent/metastatic head and neck cancer, with an objective response rate of 61.9%, one-year overall survival of 63.4%, a manageable safety profile, and plans to advance to a Phase 3 study.
Fulgent Genetics, Inc. reports that CFO and Treasurer Paul Kim had 2,747 shares of common stock withheld on July 26, 2026 to satisfy tax withholding obligations arising from the vesting of restricted stock units assumed in a 2022 merger. After this tax withholding disposition, he directly owns 359,798 shares.
Fulgent Genetics, Inc. President and COO Jian Xie reported a tax‑withholding disposition of 4,361 shares of common stock on July 26, 2026, at $19.67 per share, to cover taxes from vesting restricted stock units. After this, he directly held 363,244 shares, with an additional 220,816 shares held indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics, Inc. (FLGT) reports that Chief Scientific Officer Hanlin Gao had 1,645 shares of Common Stock withheld on July 26, 2026 to satisfy tax withholding obligations from the vesting of restricted stock units assumed in a prior merger, leaving him with 988,729 shares directly held.
Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 2,146 shares of common stock at a weighted-average price of $17.8855 per share on June 2, 2026. According to the disclosure, the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025.
Following the sale, Xie holds 367,605 shares of Fulgent Genetics common stock directly and an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.
Fulgent Genetics CFO Paul Kim reported a routine share disposition related to tax withholding. On June 1, 2026, 2,087 shares of common stock were withheld at $18.09 per share to satisfy tax obligations triggered by the vesting of restricted stock units granted on February 25, 2025. After this withholding, Kim directly holds 362,545 shares of Fulgent Genetics common stock, indicating the transaction was a small, non-market event tied to compensation rather than an open-market sale.
Fulgent Genetics, Inc. Chief Scientific Officer Hanlin Gao reported an open-market sale of 1,688 shares of common stock at a weighted-average price of $17.8855 per share. The shares were sold to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Gao directly holds 990,374 shares of Fulgent Genetics common stock.